retatrutide weight loss clinical trials retatrutide Results:Trial Data and FDA Status Retatrutide, an investigational triple hormone

Barriers Affecting Market Expansion Despite robust innovation and growth prospects, the Type 2 Diabetes market faces several enduring barriers that could constrain future expansion

Diabetes, Obesity & Metabolism, 26 (10), 44804489

The FDA will still have the final say after Lilly submits its application in the first quarter of 2027, but for the first time since this regulatory fight began, it appears that Lilly believes the path forward has finally become clear.

Two separate 20mg pens, even from the same supplier, carry the risk of minor lot-to-lot variation

This higher rate is expected when combining two appetite-suppressing compounds

The average weight loss from the drug in one trial was ~8.4kg